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Summary 
The molecular components of the quality control sys-  
tem that rapidly degrades abnormal membrane and se- 
cretory proteins have not been identified. The cystic 
fibrosis t ransmembrane conductance regulator (CFTR) 
is an integral membrane protein to which this quality 
control Is stringently applied; - 75% of the wild-type 
precursor and 100% of the AF508 CFTR variant found 
in most CF patients are rapidly degraded before exiting 
from the ER. We now show that this ER degradation 
is sensitive to inhibitors of the cytosolic proteasome, 
including lactacystin and certain peptide aldehydes. 
One of the latter compounds, MG-132, also completely 
blocks the ATP-dependent conversion of the wild-type 
precursor to the native folded form that enables es- 
cape from degradation. Hence, CFTR and presumably 
other intrinsic membrane proteins are substrates for 
proteasomal degradation during their maturation within 
the ER. 
Introduction 
One important function of intracellular protein breakdown 
is to catalyze the rapid elimination of proteins with abnor- 
mal conformations that may arise by mutations or intracel- 
lulardenaturation (Etlinger and Goldberg, 1977; Goldberg, 
1992). Such abnormal proteins in the cytosol are rapidly 
degraded by a soluble ATP-dependent pathway that in- 
volves ubiquitin and the 26s proteolytic complex (Hershko 
and Ciechanover, 1992). In this pathway, proteins are 
marked for rapid degradation by conjugation to multiple 
molecules of ubiquitin, which leads to their rapid hydrolysis 
by the 265 proteolytic complex. The proteolytic core of this 
structure is the 20s (700 kDa) proteasome, which contains 
multiple peptidase activities that function together in prote- 
olysis (for reviews see Goldberg, 1995; Goldberg et al., 
1995). Recently, several peptide aldehydes have been 
identified that can enter mammalian cells and inhibit the 
ubiquitin-proteasome pathway (Rock et al., 1994). These 
agents can block the rapid degradation of abnormal pro- 
teins completely as well as the degradation of short-lived, 
native polypeptides and the slower breakdown of the bulk 
of cell proteins (Rock et al., 1994). In contrast, inhibitors 
that affect the cysteine proteases found in lysosomes and 
the calpains have no such effects. Recently, it has been 
found that degradation of a mutant protein in the yeast 
endoplasmic reticulum (ER) membrane, Sec61, requires 
the activity of a membrane-embedded ubiquitin trans- 
ferase and the proteasome for its rapid degradation (Som- 
mer and Jentsch, 1993). Also, some surface membrane 
proteins in yeast undergo ubiquitination prior to endocyto- 
sis (Kdlling and Hollenberg, 1994). Therefore, it is also 
possible that the proteasome is critical in the turnover of 
membrane-associated proteins, especially those with 
large polypeptide domains reaching into the cytosol. 
The cystic fibrosis t ransmembrane conductance regu- 
lator (CFTR) is one such protein (Riordan et al., 1989). It 
is a secretory Cl- channel that is highly conserved among 
vertebrates (Diamond et al., 1991), where it functions as 
part of a secondary active transepithelial NaCl transport 
system (Riordan et al., 1994). Mutations in the human 
CFTR gene result in cystic fibrosis (CF) (Kerem et al., 
1989) due to a primary failure to hydrate exocrine secre- 
tions adequately. The most common mutation, AF508, 
present on at least one allele of 90% of patients (Collins, 
1992), has the primaryconsequenceof preventing biosyn- 
thetic maturation and transport beyond the ER (Cheng et 
al., 1990). However,  even with wild-type CFTR, most of 
the immature core-glycosylated molecule is not converted 
to a form capable of transport beyond the ER. Conversion 
is only - 25% efficient; the remaining - 75% of the precur- 
sor is broken down at avery rapid rate (Cheng et al., 1990) 
after translation of the polypeptide is complete (Ward and 
Kopito, 1994). Similar effects are seen both in nonpolar- 
ized cells in which CFTR cDNAs are heterologously ex- 
pressed and in epithelial cells that normally express CFTR 
(Lukacs et al., 1994; Pind et al., 1994). The ER degradation 
of AF508 occurs with the same kinetics as with the wild- 
type molecule, but AF508 is not converted to a form con- 
taining complex oligosaccharides (Cheng et al., 1990). 
The nature of the normal maturational step that enables 
movement of the wild-type protein out of the ER is not 
understood, but it does occur at the ER and is dependent 
on cellular ATP (Lukacs et al., 1994). 
Other membrane proteins are also known to be de- 
graded at the ER, but the process is poorly understood, 
and the responsible enzymes have not been identified 
(Klausner and Sitia, 1990). For example, some of these 
proteolytic events are ATP dependent (Gardner et al., 
1993), but some are not (Inoue and Simoni, 1992; Wik- 
Strom and Lodish, 1992); some occur within the lumen 
(Wikstrbm and Lodish, 1991) while others take place on 
the cytoplasmic side; some exhibit inhibitor sensitivities 
characteristic of serine proteases (Gardner et al., 1993), 
whereas others do not. In fact, the most common agents 
used to block ER proteolysis have been frequently identi- 
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fied as  cysteine protease inhibitors (Adeli, 1994;  lnoue et 
al., 1991;  W ileman et al., 1991)  al though they are also 
transition-state inhibitors of certain serine endoproteases 
and  the proteasome (Rock et al., 1994).  The  most often 
used of these pept ide aldehydes,  N-acetyCL-leucinyl-L- 
leucinyl-L-norleucinal (ALLN) and,  to a  much lesser extent, 
N-acetyl-L-leucinyl-L-leucinyl-L-methional (ALLM) have re- 
cently been  shown to also inhibit the ubiquit in-proteasome 
pathway in intact cells, as  does  another  pept ide aldehyde, 
N-carbobenzoxyl-L-leucinyl-L-leucinyl-L-leucinal (MG-I 32; 
Rock et al., 1994).  These inhibitors have  very different 
potencies for inhibition of protein degradat ion by  the pro- 
teasome. Very recently, a  highly specific, irreversible in- 
hibitor of the proteasome, lactacystin, has  been  discov- 
ered (Fenteany et al., 1995)  and  it has  not been  found to 
inhibit any  other known protease. The  present studies 
have used several of these novel  inhibitors to investigate 
whether the proteasome may also participate in the rapid 
degradat ion or processing of CFTR during its maturation. 
Results 
Effect of Peptide Aldehyde Inhibitors on  the 
Biosynthesis of W ild-Type CFTR 
W e  had  previously character ized the kinetics of degrada-  
tion and  maturation of wild-type CFTR heterologously ex- 
pressed in Chinese hamster ovary (CHO) cells and  
showed that these were not significantly different from 
those in epithelial cells that endogenously  express CFTR 
(Lukacs et al., 1994;  Pind et al., 1994).  Figure 1A shows 
that ALLN significantly retards the d isappearance of the 
- 150  kDa precursor band.  Although the loss of this band  
is markedly slowed, it is notable that all of the CFTR is 
eventually degraded in the cont inued presence of the com- 
pound,  even at doses  up  to 100  PM. The inhibition of degra-  
dation was reversed upon  removal of the inhibitor from 
the medium, as  indicated in the last three lanes in Figure 
1A. Despite the inhibition of precursor degradat ion, there 
was no  apparent  increase in the amount  of mature CFTR 
protein formed. ALLM, a  second pept ide a ldehyde inhibi- 
tor, which has  been  reported to be  completely effective 
in blocking the ER degradat ion of 3-hydroxy-3-methyl-  
glutaryl coenzyme A reductase ( Inoue et al., 1991),  was 
also tested. As can be  seen in Figure 1  B, ALLM was essen-  
tially without effect on  degradat ion of the - 150  kDa pre- 
cursor. Al though these compounds  can potently inhibit 
certain cysteine and  serine proteases (Wileman et al., 
1991)  the complete lack of inhibitory effect of ALLM sug- 
gested ALLN may be  eliciting its effect by  inhibition of 
another  protease class. Recent  studies by  Rock et al. 
(1994) demonstrated that ALLN and,  to a  much lesser ex- 
tent, ALLM also inhibit protein breakdown by purified pro- 
teasomes and  proteolysis by  the ubiquit in-proteasome 
pathway in intact cells. These observat ions seemed to 
resemble the relative inf luence of these compounds  on  
the ER degradat ion of CFTR. Therefore, another  member  
of this pept ide a ldehyde class of compounds  specifically 
developed (Palombella et al., 1994;  Goldberg et al., 1995)  
as  proteasome inhibitors, MG-132,  was tested. Figure 1C 
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Figure 1. Effects of Protease Inhibitors on  the Biosynthetic Pro- 
cessing of the Wild-Type CFTR Precursor 
CHO cells stably expressing wild-type human CFTR were pretreated 
with each of the compounds for 90  min and during a  further 30  min 
preincubation in methionine-free medium. Cells were then pulse la- 
beled (P) for 20  min with [35S]methionine and chased with methionine- 
containing medium. The absence and presence of the inhibitors are 
indicated by minus and plus signs. The designation plus/minus indi- 
cates that inhibitors were removed prior to pulse(P) and chase incuba- 
tions At the times indicated, cells were lysed and immunoprecipitated 
using the anti-CFTR monoclonal  antibody M3A7 as described pre- 
viously (Pind et al., 1994). 
(A) Decreased rate of the disappearance of the pulse-labeled immature 
band caused by 50  PM ALLN (also known as LLnL). This effect is 
almost entirely lost when the drug is removed prior to the pulse (plus/ 
minus), indicating its reversibility. 
(B) The same dose of ALLM (also known as LLM) does not delay 
degradation or maturation of the precursor. 
(C) MG-132 at 50  KM entirely prevents formation of the larger mature 
product. 
(D) Effects of inhibitors on  steady-state amounts of immature and ma- 
ture CFTR. Cells were continuously labeled with [Yi]methionine over 
an  8  hr period in a  medium composed of 75% methionine-free a-MEM, 
20% complete a-MEM, and 5% fetal bovine serum. Cell lysates were 
immunoprecipitated and electrophoresed at the end of this period. 
shows that the characteristic precursor-product relation- 
ship between the - 150  kDa immature band  and  the - 175  
kDa mature band  was altered in a  unique and  unexpected 
way bythiscompound. It completely b locked the formation 
of the mature CFTR band.  Thus,  it appears  that one  mem- 
ber  of this group of agents,  ALLN, causes a  significant 
inhibition of the rapid ER degradat ion of immature CFTR, 
whereas another  member,  MG-132,  totally blocks conver-  
sion to a  maturat ion-competent form. Blockage of this mat- 
uration step is also seen upon  ATP depletion (Lukacs et 
al., 1994).  
Since this series of compounds  inf luenced both the deg-  
radation and  conformational maturation of core-glycosylated 
CFTR in the ER, it was important to determine their steady- 
state effects. Figure 1  D shows their effect dur ing a  continu- 
ous  8  hr labeling with [YS]methionine. Consistent with its 
much greater impact on  maturation than degradat ion in 
pulse-chase experiments, virtually no  mature CFTR was 
present at the end  of an  8  hr per iod in the presence of 
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A _ MG-132 + C  _ LLnL + 
P 0.5 1 2 3 0.5 1 2 3 P123P123 
ChaseTime (h) ChaseTime (h) 
Figure 2. Effects of MG-132 and ALLN on the Degradation of the 
AF503 CFTR Precursor 
The upper member of the doublet band is the counterpart of the - 150 
kDa core-glycosylated band of the wild type. The lower member is the 
product of alternative translation initiation that is augmented in AF508 
(S. P. et al., unpublished data). MG-132 (50 PM) reduces the rate of 
degradation of the precursor bands (A and S), whereas ALLN (also 
known as LLnL) has a stronger inhibitory effect (C and D), similar 
to that on the wild type. In (6) and (D), the relative band intensities 
normalized to those after pulse labeling (lane P) were determined by 
densitometry using the PDI Discovery Series. Squares and solid lines 
represent degradation in absence of inhibitors; diamonds and broken 
lines, in their presence. 
MG-132; the amount of the immature species was also 
somewhat reduced below the control level. On  the other 
hand, ALLN, which does not prevent maturation, left the 
amount of the immature species essentially unchanged 
and that of the mature species only slightly diminished. 
Since MG-132 apparently had such a strong net effect, 
we evaluated its influence over even longer time periods 
in immunoblots (see Figure 3C). The immature form pro- 
gressively accumulates over these extended periods, and 
the amount of the mature form is diminished. To confirm 
that the proteasome was being affected by this treatment, 
we probed equivalent blots with an antibody to ubiquitin. 
The overall amount of ubiquitinated proteins was not much 
elevated until - 20 hr, when a heavy accumulation of ubi- 
quitin conjugates was evident from the top to the bottom 
of the gel (data not shown). These inhibitors have been 
shown previously to cause a similar build up of ubiquiti- 
nated proteins in other cells by inhibition of the proteasome 
pathway (A. L. G. et al., unpublished data). 
Inhibition of the Degradation of AF508 CFTR 
The major defect associated with the mutation responsible 
for most CF is its inability to undergo the maturational 
conversion that occurs with the wild-type molecule (Cheng 
et al., 1990; Kartner et al., 1992). However,  the kinetics 
of degradation of the immature unprocessed mutant mole- 
cule in the ER are not significantly different from those 
of the wild type (Lukacs et al., 1994). We evaluated the 
influence on this degradation of the two peptide aldehydes 
that had these marked effects on the wild type. Figure 2 
shows that both compounds are inhibitory, with ALLN 
again having an apparently stronger effect than MG-132. 
It is notable that under conditions in which degradation is 
most strongly blocked (e.g., ALLN at 1 hr of chase; shown 
in Figure 2C), there is a significant accumulation of very 
high molecular weight forms of CFTR evident near the top 
of the gel. These species could correspond to ubiquiti- 
nated forms of CFTR. A similar accumulation of high mo- 
lecular weight species was also detected with the ALLN- 
treated wild-type CFTR (see lane indicating 2.5 hr in Figure 
1 A), but not in ALLN-treated CHO cells that did not express 
CFTR. Despite the reduced degradation, there was no 
promotion of the maturation of AF508. 
Inhibition of Escape from ER Degradation 
We previously observed that when brefeldin A (BFA) was 
added to restrict CFTR to the ER compartment, a propor- 
tion of the immature wild-type CFTR molecules remained 
undegraded (Lukacs et al., 1994). This proportion was 
equal to that which acquired complex oligosaccharide 
chains in untreated cells, Hence, it was reasonable to de- 
duce that some essential event occurred in the ER that 
allowed CFTR to escape endogenous proteases and to 
exit from this compartment. This conversion was found to 
beATPdependent (Lukacsetal., 1994). Because MG-132 
completely prevented the conversion of the wild-type core- 
glycosylated precursor to the complex-glycosylated prod- 
uct (see Figures IC and 1D; Figure 3C), we determined 
the effect of MG-132 on this conversion that occurred in 
the ER of BFA-treated cells. Figure 3A clearly demon- 
strates that, in the presence of MG-132, the fraction of 
CFTR that is normally retained intact becomes completely 
degraded. Because this step, which we interpreted previ- 
ously as conformational maturation, is blocked by MG-132, 
it probably involves proteolytic cleavage. One possible in- 
terpretation is that MG-132 acts on an ATP-dependent 
protease that mediates the conversion. A number of such 
enzymes have been found in bacteria and mitochondria 
of eukaryotic cells (Goldberg, 1992). Alternatively, the 
ATP-mediated step may involve Hsp70, which associates 
with immature CFTR (Yang et al., 1993). Dissociation of 
the chaperone from the cytoplasmic aspect of the ER re- 
quires ATP hydrolysis and might be necessary to allow 
the maturation step to occur. In a similar experiment in 
which ALLN instead of MG-132 was added to BFA-treated 
cells (Figure 3B), the result was quite different. A similar 
proportion of the initial pulse-labeled material was retained 
in the presence and absence of this peptide aldehyde, 
although there was significantly reduced pulse labeling of 
CFTR in its presence. Because the MG-132sensit ive step 
that is responsible for escape from complete degradation 
at the ER is insensitive to ALLN, this step must be different 
from the degradative process that is sensitive to both of 
these compounds (see Figure 2). 
Effects of Lactacystin on CFTR Biosynthesis 
Very recently, a Streptomyces metabolite with interesting 
cytological effects was demonstrated to be a highly spe- 
cific inhibitor of multiple proteasome activities (Fenteany 
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Figure 3. Effect of Peptide Aldehydes on the ER Degradation of the 
Wild-Type CFTR Precursor in BFA-Treated Cells and on Steady-State 
CFTR Levels in Untreated Cells 
Experimental conditions were as in Figure 1 except that 10 uM BFA 
was present in all samples in (A) and (B) from the outset. 
(A) MG-132 prevents the persistence of a portion of core-glycosylated 
CFTR in BFA-treated cells. 
(B) The proportion of pulse-labeled precursor (lane P) retained after 
5 hr of chase in BFA-treated cells is not diminished by ALLN (also 
known as LLnL), although the extent of pulse labeling is reduced. 
(C) Cells were continuously exposed to MG-I32 for the periods indi- 
cated and lysates immunoblotted using the M3A7 anti-CFTR antibody. 
The amount of mature CFTR progressively decreased and the imma- 
ture form accumulated. 
et al., 1995). In view of the profound but distinct effects of 
different peptide aldehyde inhibitorson CFTR processing, 
we examined the influence of lactacystin in the identical 
experimental paradigm. The results of one such experi- 
ment are shown in Figures 4A and 46. Lactacystin caused 
a somewhat greater inhibition of precursor degradation 
than did ALLN. Its net effect during longer term continuous 
labeling (8 hr) was similar to that of ALLN (see Figure 1 D). 
Thus, the 20s proteasome does contribute substantially 
to the rapid turnover of the CFTR precursor at the ER. This 
result provides stronger evidence that the maturational 
processing step that allows escape from bulk degradation 
must reflect another proteolytic activity that is sensitive to 
MG-132 but presumably distinct from the proteasome. It 
is very clear that lactacystin does not inhibit conversion 
of the immature to the mature form. Nevertheless, like the 
other less potent inhibitors, it also does not significantly 
promote the accumulation of mature forms; consequently, 
there must be additional quality control steps in this 
pathway. 
Comparison with P-Glycoprotein Maturation 
As shown above, characteristic features of CFTR biosyn- 
thesis are rapid breakdown of the immature form and its 
inefficient conversion to the mature form. A structurally 
related integral membrane glycoprotein, the wild-type P-gly- 
coprotein (P-gp) multidrug transporter, does not exhibit 
this behavior (Loo and Clarke, 1994). As shown in Figure 
4C, there is a very efficient conversion of immature P-gp 
into a complex glycosylated form during a pulse-chase 
experiment. We tested the influence of MG-132 on this 
maturation. While there is some slowing of the maturation 
of P-gp, the effect is much smaller than in the case of 
CFTR. It will be interesting in future experiments to deter- 
mine whether the degradation of variants of P-gp created 
by in vitro mutagenesis that fail to mature (Loo and Clarke, 
1994) is sensitive to proteasome inhibitors. However,  from 
the present observations, the step that CFTR must un- 
dergo to avoid degradation by the proteasome and possi- 
bly additional proteases appears to be at least somewhat 
specific. Possibly, the ATP-requiring, MG-132-sensit ive 
pathway involves processing of the CFTR molecule itself. 
However,  CFTR is not believed to be cleaved N-terminally, 
although peptide sequencing has been performed only 
on the recombinant protein expressed in insect Sf9 cells 
(Bear et al., 1992). Antibodies against peptides as close 
to the N-terminus as residues 28-45 recognize mature 
CFTR (Kartner et al., 1991; S. P. et al., unpublished data), 
as do those raised against the extreme C-terminus (Cohn 
et al., 1991). Investigations of other possibilities, including 
ttie cleavage of chaperones or other interacting ER pro- 
teins, will be a primary goal of future work. 
A _Lactacystin+ C -MG-132 (P-gp)+ 
P123P123 P 0.5 1 2 3 P 0.5 1 2 3 
Chase Time (h) 
Figure 4. Effects of Proteasome Inhibitors on CFTR and P-gp Pro- 
cessing 
(A) The proteasome-specific inhibitor lactacystin applied at 10 FM, 
using the same preincubation protocol described in Figure 1, strongly 
inhibited degradation of wild-type CFTR precursor but not its matura- 
tion. P, pulse. 
(B) Graphical representation of relative band intensities in (A). Squares 
represent precursor degradation in the absence of drug; circles, in its 
presence. Diamonds represent product accumulation in the absence 
of drug; triangles, in its presence. 
(C) MG-132 at the same concentration (50 PM) that totally blocked 
CFTR maturation did not abolish P-gp maturation. 
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Discussion 
It is now clear that the proteasome is the primary site in 
mammalian cells for degradation of cytosolic and nuclear 
proteins (Rock et al., 1994). It is responsible for the degra- 
dation of many rapidly turning-over proteins in cells, espe- 
cially regulatory molecules such as the cyclins (Hershko 
et al., 1994). It can also catalyze limited proteolytic pro- 
cessing that generates the active form of molecules, such 
as production of the 50 kDa subunit of the transcription 
factor, NF-KB, from the 105 kDa precursor (Palombella et 
al., 1994). In view of such a processing function and the 
fact that several membrane proteins are ubiquitinated 
prior to their degradation (Kijlling and Hollenberg, 1994; 
Sommer and Jentsch, 1993) or activation (Paolini and Ki- 
met, 1993; Hou et al., 1994), it may not be surprising that 
the ubiquitin-proteasome pathway is involved in the deg- 
radation and perhaps also in the proteolytic processing 
of CFTR. We have provided substantial pharmacological 
evidence that the proteasome participates in the complete 
hydrolysis of the ER form of CFTR. Although ER degrada- 
tion has been widely assumed to involve lumenal cysteine 
proteases, nearly 85% of the mass of CFTR is believed 
to be exposed on the cytoplasmic surface of the ER, where 
proteasome particles also have been directly observed by 
immunoelectromicroscopy (Rivett, 1993). One can imag- 
ine these particles docking on the cytoplasmically exposed 
domains that may be marked for degradation, perhaps by 
ubiquitination. The abundant chaperone, Hsp70, can bind 
the ER form of CFTR from the cytosolic side (Yang et al., 
1993), and recent studies in eukaryotic cells as well as 
bacteria show that Hsp70 and its cofactors in the dnaK 
family are required for rapid degradation of certain cyto- 
solic and ER proteins (Sherman and Goldberg, 1992, 
1995). 
Although immature CFTR appears to be ubiquitinated, 
as suggested by the appearance of high molecular weight 
forms, at least after treatment with the more potent protea- 
some inhibitors, we have not yet established whether the 
rapid breakdown of wild-type and mutant CFTR requires 
ubiquitination. There are examples of ubiquitination and 
proteasomal degradation not being obligatorily coupled. 
Importantly, the rapidlyturning-overSTEGsurfaceprotein, 
astructural relative of CFTR, is ubiquitinated, but its degra- 
dation involves endocytosis and hydrolysis in the yeast 
vacuole, the counterpart of the mammalian cell lysosome 
(Kblling and Hollenberg, 1994). Conversely, ornithine de- 
carboxylase (Murakami et al., 1992) and perhaps other 
polypeptides (e.g., the model polypeptide casein; Driscoll 
and Goldberg, 1990) are degraded by the 26s proteasome 
in an ubiquitination-independent fashion. 
These findings with CFTR seem to indicate that the sub- 
strate range of the proteasome includes some membrane 
and possibly secretory proteins at a relatively early stage 
of their biosynthetic processing in the ER. However,  other 
proteolytic systems probably also contribute to ER quality 
control. In the cases of membrane proteins in which very 
little of the polypeptide is exposed on the cytoplasmic side 
of the ER membrane, a primary role for the proteasome 
would seem unlikely, although it might be possible that crit- 
ical cleavages on the cytosolic side could make the Iu- 
menal parts more susceptible to proteases within the ER. 
It will now be of interest to determine what role the protea- 
some plays in the breakdown in the ER of other membrane 
proteins such as the asialoglycoprotein receptor (Wikstrijm 
and Lodish, 1992), 3-hydroxy-3-methyl-glutaryl coenzyme 
A reductase, and T cell receptor a (Inoue and Simoni, 
1992). 
In addition to demonstrating that the proteasome contri- 
butes to the ER degradation of an intrinsic membrane pro- 
tein, these experiments have provided insights into the 
steps involved in the handling of wild-type and AF508 
CFTR at the ER and the sequence in which they occur. 
A clear inhibition of precursor degradation is caused by 
the proteasomal inhibitors lactacystin, ALLN, and MG- 
132, but in no case does this inhibition result in increased 
conversion to the mature form. Therefore, there must be 
a second degradation pathway functioning in parallel with 
the proteasome. It is apparently ATP independent, as it is 
very active in ATP-depleted cells treated with proteasome 
inhibitors such as lactacystin (our unpublished data). Con- 
version of the precursor to the native folded form capable 
of transport from the ER is completely ATP dependent 
(Lukacs et al., 1994) and inhibited entirely by MG-132 (see 
Figure lC), but not by the other proteasome inhibitors 
tested. Hence, at least three proteolytic steps may contrib- 
ute to the ER processing of CFTR. The MG-132-sensit ive, 
ATP-requiring one seems to provide an escape route from 
the other two and hence must occur before they do. Nor- 
mally, only a minority of the wild-type precursor molecules 
escape and mature; those that do not may be digested 
by either of the ER-associated degradative processes; if 
the proteasome is inhibited, the ATP-independent path- 
way is accelerated. These findings raise the intriguing pos- 
sibility that, at the ER, the balance between rapid degrada- 
tion and maturation of the core-glycosylated immature 
polypeptide is determined by competitive proteolytic pro- 
cesses whose activities may be sites of physiological regu- 
lation. 
Experimental Procedures 
Cells and Media 
The CHO cell lines stably expressing wild-type and AF508 CFTR de- 
scribed previously (Chang et al., 1993; Pind et al., 1994; Tabcharani et 
al., 1991) were grown in a-minimal essential medium (MEM) containing 
7% fetal bovine serum (Sigma). The 830 multidrug-resistant cells that 
overexpress P-gp were those developed by Kartner et al. (1985); they 
were grown in nucleoside-supplemented a-MEM. 
Antibodies 
The mouse monoclonal antibody M3A7, which recognizes an epitope 
between amino acid residues 1365 and 1394 on human CFTR, devel- 
oped and characterized earlier (Kartner et al., 1992), was purified from 
ascites by chromatography on protein A-Superose (Pharmacia) and 
Mono Q (Pharmacia). Mouse monoclonal antibodies to BiP (grp78) and 
a rabbit polyclonal antibody to calnexin ware obtained from StressGen, 
and a mouse monoclonal antibody to bovine ubiquitin was obtained 
from Chemicon International. The mouse monoclonal antibody C219 
(Kartner et al., 1985), specific for P-gp, was from Signet Laboratories. 
[35S]Methionine Incorporation 
Cell monolayers were starved for 30 min in methionine-free a-MEM 
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and then pulse labeled for 20 min with 100 @/ml L-[%]methionine 
(>800 Cilmmol; Amersham). To chase, this medium was replaced with 
a-MEM containing 7% fetal bovine serum and 1 mM methionine. Pulse 
and chase incubations as well as preincubations were performed in 
a 37OC incubator with 5% CO,. 
Treatment with Protease Inhibitors 
ALLN and ALLM (Sigma) and MG-132 and lactacystin (Myogenics) 
were dissolved in DMSO. These were added to cells usually 90 min 
prior to methionine starvation and, except in experiments to detect 
reversibility, were also present during the pulse labeling and chase 
periods. Final DMSO concentrations were 1% or less and, in the ab- 
sence of the inhibitors, were without influence on CFTR processing. 
Cell Lysis and lmmunoprecipitation 
Cells were solubilized in RIPA buffer consisting of 50 mM Tris-HCI 
(pH 7.4)containing 150mM NaCI, 1% sodium deoxycholate, l%Triton 
X-100, and 0.1% sodium lauryl sulfate. Detergents were from Sigma. 
This buffer contained the following protease inhibitors: leupeptin (10 
uglml), aprotinin (5 Kg/ml), and Prefabloc (50 Kg/ml), all from Boeh- 
ringer Mannheim, and benzamidine (100 kg/ml) and E84 (3.5 Kg/ml), 
from Sigma. The soluble supernatant obtained after centrifugation at 
15,000 x g for 15 min at 4°C was incubated at the same temperature 
with 1 uglml purified M3A7 (or C219 in the case of P-gp labeling). 
The complexes formed were then bound to protein G-agarose beads 
(GIBCO BRL) and washed four times with RIPA buffer prior to incuba- 
tion at room temperature with electrophoresis sample buffer. 
SDS-PAGE and lmmunoblotting 
lmmunoprecipitates for [35S]methionine-labeled cells were dissolved 
at room temperature in electrophoresis sample buffer as described 
previously (Pind et al., 1994) and separated by SDS-PAGE on 7% 
polyacrylamide gels that were then fixed in 30% methanol and 10% 
acetic acid, equilibrated in 1 M  sodium salicylate, and dried for fluorog- 
raphy (Pind et al., 1994). For Western blotting, nonradioactively la- 
beled cell lysates were dissolved in the same electrophoresis sample 
buffer, electrophoresed, and transferred to nitrocellulose membranes 
(Bio-Rad). The membranes were probed with the primary antibodies 
described above to CFTR, P-gp, BiP, calnexin, and ubiquitin, and 
the bound antibodies were detected by enhanced chemiluminescence 
(Amersham) using protocols described in detail previously (Kartner et 
al., 1991). 
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